Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ OTHER NEUROSCIENCE — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER IMMUNOLOGY
$46M+4,500%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

AbbVie logo
ABBVOther Neuroscience — Net revenues
$125M-19.4%
Eli Lilly logo
LLYNeuroscience — Revenue
$382M+40.4%
Medtronic logo
MDTNeuroscience — Net Sales
$2.75B+5.0%
Lantheus Holdings logo
LNTHNeurology — Revenue
$35.44M—
Supernus Pharmaceuticals logo
SUPNNet product sales — Total revenues
$150.75M+6.2%
IAR
IARTNeurosurgery — Total Revenues
$198.2M+3.8%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's other neuroscience — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's OTHER NEUROSCIENCE — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported OTHER NEUROSCIENCE — sales to customers (note 9) of $262M in Q1 2026.
How has Johnson & Johnson's OTHER NEUROSCIENCE — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's OTHER NEUROSCIENCE — sales to customers (note 9) decreased by 5.4% year-over-year, from $277M to $262M.
What is the long-term trend for Johnson & Johnson's OTHER NEUROSCIENCE — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's OTHER NEUROSCIENCE — sales to customers (note 9) has grown at a -15.7% compound annual growth rate (CAGR), from $2.07B to $1.05B.
What does OTHER NEUROSCIENCE — sales to customers (note 9) mean?
This metric represents the total net revenue generated from the sale of products within the company's secondary neuroscience portfolio. It captures the financial performance of specialized neurological therapeutic offerings that fall outside of the primary flagship neuroscience franchises. Tracking this revenue stream helps investors assess the diversification and growth potential of the company's broader neurological product pipeline.